AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this year, outperforming the S&P 500 and Nasdaq 100 indices.

For this analysis, we will use AbbVie’s stock price $117.93 (8/19/21 close). Analysts are projecting forward EPS of $12.65 per share. The company’s annual dividend is $5.20 per share.

ABBV Quantitative Stock Analysis July 02, 2024 — 10:00 am EDT. Written by John Reese for Validea -> Below is Validea's guru fundamental report for ABBVIE INC . Of ...

AbbVie has strong growth potential in various therapeutic and aesthetic markets, driven by novel drugs and market penetration. Read why ABBV stock is a hold.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

AbbVie Inc ABBV released on Saturday the final analysis of the confirmatory Phase 3 MIRASOL trial of Elahere ... ABBV Price Action: AbbVie stock is up 1.63% at $212.23 at publication Monday.

ABBV Quantitative Stock Analysis August 06, 2024 — 09:35 am EDT. ... Detailed Analysis of ABBVIE INC. ABBV Guru Analysis. ABBV Fundamental Analysis. More Information on Partha Mohanram.

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

AbbVie is expected to post earnings of $3.11 per share for the current quarter, representing a year-over-year change of +17.4%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.3%.